Actively Recruiting
Early Phase 0 Study to Evaluate How Acetadote Affects Metabolism in Newly Diagnosed Glioblastoma Using MRI and Tumor Tissue Analysis
Led by University of Texas Southwestern Medical Center · Updated on 2026-06-23
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying how Acetadote affects metabolism in patients newly diagnosed with glioblastoma, a type of brain tumor. The study aims to understand how Acetadote, which may influence cell damage from oxidative stress, changes the metabolism of brain tumors. This early-phase clinical trial uses advanced MRI techniques to observe these metabolic effects. Participants will receive Acetadote at a dose of 150 mgkg given through an intravenous infusion over one hour. The drug is administered twice once before magnetic resonance spectroscopy MRS on the first day, and again before surgical removal of the tumor, which occurs between 2 to 21 days later. This allows researchers to study the impact of Acetadote on tumor metabolism both before and during surgery. During the study, participants will undergo MRS imaging and provide tumor tissue samples during surgery, which are analyzed to measure metabolic changes caused by Acetadote. Researchers will monitor outcomes from the day of the first dose up to 21 days after. Participants must meet specific health criteria, and the study includes safety assessments and informed consent processes. The trial is expected to conclude by July 2028.
CONDITIONS
Brief Title
Imaging Acetadote Metabolism in Glioblastoma
Research Team
O
Omar Raslan, MBBCH, MPH, CCRP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
